Hengrui medicine advances drug, revises company charter and governance

Jiangsu Hengrui Medicine's board of directors approved key proposals on December 10, 2025, including amendments to the company charter and a resolution to hold its second extraordinary general meeting of shareholders for 2025. This reflects ongoing adjustments to corporate governance and strategic direction.

The company charter amendments expand the business scope to include the "research, manufacturing, and sales of pharmaceutical packaging materials and products." The Supervisory Board will also be removed, with its functions transferred to the Board of Directors' Audit Committee. Additionally, the charter updates reflect the company’s capital structure, with a registered capital of RMB 6,637,199,874, and clarifies shareholder rights and responsibilities.

Further demonstrating its commitment to innovation, Jiangsu Hengrui Medicine’s subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received clinical trial approval for HRS9531 injection. This dual agonist, targeting GIPR and GLP-1R, is intended for metabolic dysfunction-associated steatohepatitis (MASH). With a cumulative R&D investment of approximately RMB 51,854 million, HRS9531 aims to improve blood glucose, reduce weight, and mitigate hepatic lipid accumulation and inflammation.